Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Notes Payables (2023 - 2025)

Lucid Diagnostics' Notes Payables history spans 3 years, with the latest figure at $24.0 million for Q4 2025.

  • For Q4 2025, Notes Payables rose 29.03% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $24.0 million, up 29.03%, while the annual FY2025 figure was $24.0 million, 29.03% up from the prior year.
  • Notes Payables reached $24.0 million in Q4 2025 per LUCD's latest filing, up from $22.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $32.8 million in Q1 2025 to a low of $10.2 million in Q3 2024.
  • Average Notes Payables over 3 years is $17.5 million, with a median of $14.2 million recorded in 2023.
  • Peak YoY movement for Notes Payables: dropped 29.61% in 2024, then surged 150.38% in 2025.
  • A 3-year view of Notes Payables shows it stood at $14.0 million in 2023, then soared by 33.33% to $18.6 million in 2024, then increased by 29.03% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Notes Payables are $24.0 million (Q4 2025), $22.3 million (Q3 2025), and $25.3 million (Q2 2025).